GENPHARMASEC LIMITED (GENPHARMA)

BSE: ₹1.14
Stock Performance
Corporate Announcements
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for the year ended March 31, 2026.

2026-05-27 16:13:42
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March, 2026.

2026-05-23 10:53:10
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St March, 2026.

Statement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March, 2026.

2026-05-21 17:40:59
Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended 31St March, 2026.

Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March, 2026.

2026-05-21 17:35:22
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On Thursday, May 21, 2026.

Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.

2026-05-21 17:26:40
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, 21St May, 2026.

1. To consider, approve & take on record the Audited Standalone and Consolidated Financial Results of the Company along with the Auditor’s Report thereon, for the Quarter and Year ended 31st March, 2026. 2. To consider any other business with the permission of a Chairman of the Meeting.

2026-05-13 11:37:41
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGenpharmasec Ltd 2CIN NO.L24231MH1992PLC323914 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Hardik Makwana Designation: Company Secretary and Compliance Officer EmailId: compliance@genpharmasec.com Name of the Chief Financial Officer: Mr Sohan Chaturvedi Designation: Chief Financial Officer EmailId: Sohan.chaturvedi@genpharmasec.com Date: 14/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

2026-04-14 15:45:21
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended March 31, 2026.

2026-04-08 10:54:00
Closure of Trading Window

Intimation of closure of Trading window.

2026-03-26 12:24:48
Outcome Of Separate Meeting Of Independent Directors Of The Company.

Outcome of Separate Meeting of Independent Directors held on March 24, 2026.

2026-03-24 11:42:41

Quarterly Financials

Consolidated Standalone
Particulars Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 10.20 5.19 6.03 8.48 14.01 12.04 32.64 39.83 55.43
YOY Revenue Growth % - - - - 37.37% 131.82% 440.97% 369.45% 295.65%
Other Income 0.31 0.57 0.75 0.81 0.94 0.69 0.46 0.98 1.02
Total Income 10.51 5.76 6.78 9.30 14.95 12.74 33.10 40.81 56.44
Total Expenses + 10.40 5.27 6.28 8.00 15.37 11.49 33.90 42.14 54.59
Cost of Materials Consumed 0.00 0.00 0.11 0.02 0.38 0.13 0.89 1.70 0.12
Employee Benefit Expense 0.16 0.18 0.19 0.31 0.31 0.35 1.20 1.25 1.07
Other Expenses 1.86 0.69 0.73 1.01 0.74 0.92 1.54 2.06 2.22
Operating Profit -0.20 -0.08 -0.24 0.48 -1.36 0.55 -1.26 -2.31 0.84
OPM % -2% -1.5% -4% 5.7% -9.7% 4.6% -3.9% -5.8% 1.5%
Profit Before Tax + 0.11 0.49 0.50 1.29 -0.43 1.25 -0.80 -1.33 1.85
Tax Expense 0.38 0.20 -0.20 0.51 -0.15 0.03 0.38 -0.50 0.50
Tax % 341.8% 41.1% -39.4% 39.6% - 2.5% - - 27%
Profit After Tax -0.27 0.29 0.70 0.78 -0.27 1.22 -1.18 -0.83 1.35
EPS (Basic) 0.00 0.01 0.01 0.01 -0.01 0.02 -0.02 -0.02 0.02

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024
Revenue from Operations 139.94 33.72 30.41
YOY Revenue Growth % 314.98% 10.91% -
Other Income 3.16 3.06 0.66
Total Income 143.09 36.78 31.06
Total Expenses + 142.12 34.90 30.81
Cost of Materials Consumed 2.84 0.87 0.00
Employee Benefit Expense 3.87 0.99 0.76
Other Expenses 6.27 3.12 5.36
Operating Profit -2.19 -1.18 -0.41
OPM % -1.6% -3.5% -1.3%
Profit Before Exceptional 0.97 1.88 0.25
Exceptional Items 0.00 0.00 0.00
Profit Before Tax + 0.97 1.88 0.25
Tax Expense 0.41 0.65 0.42
Tax % 42.3% 34.5% 167.6%
Profit After Tax 0.56 1.23 -0.17
EPS (Basic) 0.01 0.01 0.00

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024
ASSETS
Non-Current Assets + 57.63 51.74 30.28
Property, Plant & Equipment 21.31 5.56 0.84
Capital Work in Progress 0.00 0.00 0.00
Non-Current Investments 1.58 18.84 0.00
Goodwill 18.12 0.00 0.00
Other Intangible Assets 0.00 0.00 0.00
Current Assets + 80.52 28.16 40.85
Inventories 13.88 8.20 8.84
Trade Receivables 29.27 13.60 9.10
Cash and Cash Equivalents 0.97 0.65 3.17
Current Investments 0.00 0.00 1.68
LIABILITIES & EQUITY
Total Equity 65.64 65.28 64.53
Equity Share Capital 55.37 55.37 55.37
Other Equity 10.89 9.79 9.02
Non-Current Liabilities 25.48 4.78 3.89
Current Liabilities 47.03 9.84 2.70
Total Liabilities 72.51 14.61 6.59

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024
Cash from Operating Activities -17.55 3.00 -3.68
Cash from Investing Activities 13.26 -15.31 -27.35
Cash from Financing Activities 3.92 -1.25 47.86
Net Increase/Decrease in Cash -0.37 -13.56 16.84